WAVE.V · Waverley Pharma Inc

-

Please sign in to comment on WAVE.V

1 Comment

Admin

3 years, 7 months ago

Waverley Pharma Inc is currently in a long term downtrend where the price is trading 20.0% below its 200 day moving average.

From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.

Waverley Pharma Inc's total revenue rose by 33.7% to $353K since the same quarter in the previous year.

Its net income has increased by 100.2% to $989 since the same quarter in the previous year.

Finally, its free cash flow grew by 129.3% to $179K since the same quarter in the previous year.

Based on the above factors, Waverley Pharma Inc gets an overall score of 4/5.

Sector	Healthcare
Industry	Biotechnology
ISIN	CA94357L1058
CurrencyCode	CAD
Exchange	V

Dividend Yield	0.0%
Target Price	10
PE Ratio	None
Market Cap	2M
Beta	1.48

ABOUT

Waverley Pharma Inc

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes cancer therapeutics in the United Kingdom, European Union, and North America. It focuses on the generic oncology injectable products. The company sells generic oncology products comprising capecitabine, temozolomide, and erlotinib. Its products under development include injectable generic chemotherapy drugs, such as Pemetrexed for the treatment of non-small cell lung cancer and pleural mesothelioma; and Bortezomib to treat multiple myeloma and mantle cell lymphoma. The company has a collaboration agreement with the University of Manitoba for the development of a synthetic library of chloroquine analogs to treat COVID-19. Waverley Pharma Inc. is headquartered in Winnipeg, Canada.

WAVE.V · Waverley Pharma Inc

-

Waverley Pharma Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Waverley Pharma Inc using a moving average strategy